HOWL vs. PYXS, RANI, NKTR, ACET, STTK, CNTA, ETNB, CVAC, EOLS, and PRTC
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Pyxis Oncology (PYXS), Rani Therapeutics (RANI), Nektar Therapeutics (NKTR), Adicet Bio (ACET), Shattuck Labs (STTK), Centessa Pharmaceuticals (CNTA), 89bio (ETNB), CureVac (CVAC), Evolus (EOLS), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.
In the previous week, Pyxis Oncology and Pyxis Oncology both had 5 articles in the media. Werewolf Therapeutics' average media sentiment score of 1.00 beat Pyxis Oncology's score of 0.39 indicating that Pyxis Oncology is being referred to more favorably in the media.
Pyxis Oncology has a net margin of 0.00% compared to Pyxis Oncology's net margin of -256.33%. Pyxis Oncology's return on equity of -36.15% beat Werewolf Therapeutics' return on equity.
39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 9.3% of Pyxis Oncology shares are owned by insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Pyxis Oncology currently has a consensus target price of $8.80, indicating a potential upside of 135.29%. Werewolf Therapeutics has a consensus target price of $12.00, indicating a potential upside of 132.11%. Given Werewolf Therapeutics' higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Werewolf Therapeutics.
Werewolf Therapeutics has higher revenue and earnings than Pyxis Oncology. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Werewolf Therapeutics received 4 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 63.16% of users gave Werewolf Therapeutics an outperform vote.
Pyxis Oncology has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
Summary
Werewolf Therapeutics beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
